首页> 外文期刊>Journal of Pure & Applied Microbiology >Anti-Biofilm Activity of Lactic Acid Bacteria Isolated from Kefir Against Multidrug-Resistant Klebsiella pneumoniae
【24h】

Anti-Biofilm Activity of Lactic Acid Bacteria Isolated from Kefir Against Multidrug-Resistant Klebsiella pneumoniae

机译:抗生物膜活性乳酸菌与kefir对多药抗性克雷布氏菌肺炎的乳酸菌

获取原文
获取原文并翻译 | 示例
           

摘要

Bacterial biofilms gained attention in the medical field with the emergence of antibiotic-resistant strains. The potency of lactic acid bacteria (LAB), isolated from kefir, against the development of a biofilm populated by the multidrug-resistant (M DR) Klebsiella pneumoniae was accessed in this study. The ability of LAB to inhibit biofilm formation was screened using the crystal violet method, and the morphology of the biofilms was analyzed using electron microscopy. Cell viability of K. pneumoniaeafter administration of LAB cell free supernatant was determined by MTT assay. Lactobacillus isolates were characterized using partial sequencing against 16S rRNA. Quorum sensing inhibition of K. pneumoniae by LAB was conducted with the help of the AHL reporter strain. Result showed that addition of cell free supernatant (CFS) as well as pellet of 40 isolates LAB on to K. pneumoniae culture could decrease their culture absorbance. Among those isolates, LAB G24 and G25 from grain kefir and LAB K10 and K15 from milk kefir demonstrated the strongest effect by reducing the absorbance by eight to nine-fold. Analysis of biofilm morphology showed that the CFS of Lactobacillus could prevent the attachment between K. pneumoniae cells. In addition, cell viability of K. pneumoniae was significantly reduced after the addition of the LABs CFS. Partial sequencing of 16S rRNA identified the LAB isolate as Lactobacillus helveticus. In conclusion the L. helveticus isolated from kefir demonstrated anti-biofilm activityagainst MDR K. pneumoniae. L. helveticus are potential probiotic strains for therapeutic application in the clearance of MDR K. pneumoniae.
机译:通过抗生素抗性菌株的出现,细菌生物膜在医学领域进行了关注。本研究进入了乳房乳酸菌(实验室),与Kefir中分离的乳酸菌(实验室)的效力来自kefir的发育,抗软抗体(M博士)肺炎肺炎。使用晶体紫色方法筛选实验室抑制生物膜形成的能力,使用电子显微镜分析生物膜的形态。通过MTT测定法测定K.肺炎细胞活力施用实验室细胞自由上清液。使用针对16S rRNA的部分测序来表征乳杆菌病症的特征。通过AHL报告菌株对实验室进行K.Pneumoniae的批量传感抑制。结果表明,添加细胞无清洁剂(CFS)以及40个分离株实验室的颗粒可以降低其培养吸光度。在这些分离物中,来自谷物Kefir的实验室G24和G25和来自牛奶Kefir的Lab K10和K15通过将吸光度降低8至9倍来证明了最强的效果。生物膜形态的分析表明,乳酸杆菌的CFS可以防止K.肺炎细胞之间的附着。此外,在添加实验室CFS后,K.Pneumoniae的细胞活力显着降低。 16S RRNA的部分测序鉴定了实验室分离为乳杆菌Helveticus。总之,从克维尔中分离的L. Helveticus证明了抗生物膜致敏性MDR K.Pneumoniae。 L. Helveticus是潜在的益生菌菌株,用于治疗MDR K.肺炎的清除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号